Karl Mullen’s work focuses on patent infringement litigation and IP counseling. Prior to starting his legal career Mr. Mullen worked as a Senior Research Associate for the International AIDS Vaccine Initiative, as a Research Assistant in the Vaccine and Gene Therapy Institute at OHSU (Oregon Health and Science University), and as a Lab Manager at the University of Montana. Before joining Desmarais LLP Mr. Mullen worked as a Technical Advisor for the Mullen Law Firm, PC, Beaverton, Oregon.
- Park, et al. 2013. Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. J Immunol. 190(8):4103-15.
- Winstone, et al. 2011. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J. Virol. 85(18):9578-87.
- Geng, H., Zhu, Y., Mullen, K., Zuber, C., Nakano, M. 2007. Characterization of ResDE-Dependent fnr transcription in Bacillus subtilis. J. Bacteriology 189(5):1745-55.
- Bentley, M., Liang, Y., Mullen, K., Xu, D., Sztul, E., Hay, J. 2006. SNARE status regulates tether recruitment and function in homotypic COPII vesicle fusion. J. Biol. Chem. 281(50):38825-33.
- Yu, S., Satoh, A., Pypaert, M., Mullen, K., Hay, J., Ferro-Novick, S. 2006. mBet3p is required for homotypic COPII vesicle tethering in mammalian cells. J. Cell Biol. 174(3):359-68.